|
Solvent |
mg/mL |
mM |
Solubility |
DMSO |
33.3 |
90.96 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
366.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Davidson M, Saoud J, Staner C, Noel N, Werner S, Luthringer E, Walling D,
Weiser M, Harvey PD, Strauss GP, Luthringer R. Efficacy and Safety of
Roluperidone for the Treatment of Negative Symptoms of Schizophrenia. Schizophr
Bull. 2022 May 7;48(3):609-619. doi: 10.1093/schbul/sbac013. PMID: 35211743;
PMCID: PMC9077422.
2: Rabinowitz J, Staner C, Saoud J, Weiser M, Kuchibhatla R, Davidson M, Harvey
PD, Luthringer R. Long-term effects of Roluperidone on negative symptoms of
schizophrenia. Schizophr Res. 2023 May;255:9-13. doi:
10.1016/j.schres.2023.03.028. Epub 2023 Mar 16. PMID: 36933291.
3: Harvey PD, Saoud JB, Luthringer R, Moroz S, Blazhevych Y, Stefanescu C,
Davidson M. Effects of Roluperidone (MIN-101) on two dimensions of the negative
symptoms factor score: Reduced emotional experience and reduced emotional
expression. Schizophr Res. 2020 Jan;215:352-356. doi:
10.1016/j.schres.2019.08.029. Epub 2019 Sep 2. PMID: 31488314.
4: James SH, Ahmed AO, Harvey PD, Saoud JB, Davidson M, Kuchibhatla R,
Luthringer R, Strauss GP. Network intervention analysis indicates that
roluperidone achieves its effect on negative symptoms of schizophrenia by
targeting avolition. Eur Neuropsychopharmacol. 2024 Oct;87:18-23. doi:
10.1016/j.euroneuro.2024.07.005. Epub 2024 Jul 17. PMID: 39024856.
5: Strauss GP, Zamani Esfahlani F, Sayama H, Kirkpatrick B, Opler MG, Saoud JB,
Davidson M, Luthringer R. Network Analysis Indicates That Avolition Is the Most
Central Domain for the Successful Treatment of Negative Symptoms: Evidence From
the Roluperidone Randomized Clinical Trial. Schizophr Bull. 2020 Jul
8;46(4):964-970. doi: 10.1093/schbul/sbz141. PMID: 31989151; PMCID: PMC7342174.
6: Rabinowitz J, Badescu S, Palamarchuk P, Filyk V, Voloshchuk A, Rud V, Melnyk
E, Skrypnikov A, Davidson M, Saoud J, Luthringer R. Personal and social
adjustment effects of roluperidone in patients with schizophrenia and negative
symptoms: Results from an exploratory outcome of a randomized placebo-controlled
trial. Schizophr Res. 2019 Sep;211:103-104. doi: 10.1016/j.schres.2019.07.029.
Epub 2019 Jul 30. PMID: 31375316.